Nemes Rush Group LLC Has $38,000 Stake in Amgen Inc. $AMGN

Nemes Rush Group LLC lowered its position in shares of Amgen Inc. (NASDAQ:AMGN) by 73.2% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 135 shares of the medical research company’s stock after selling 368 shares during the period. Nemes Rush Group LLC’s holdings in Amgen were worth $38,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of AMGN. Fairvoy Private Wealth LLC increased its stake in shares of Amgen by 1.1% in the second quarter. Fairvoy Private Wealth LLC now owns 3,171 shares of the medical research company’s stock valued at $885,000 after buying an additional 35 shares during the period. Nicholson Wealth Management Group LLC increased its position in Amgen by 0.6% in the 2nd quarter. Nicholson Wealth Management Group LLC now owns 5,918 shares of the medical research company’s stock valued at $1,652,000 after acquiring an additional 35 shares during the period. Crumly & Associates Inc. increased its position in Amgen by 3.2% in the 2nd quarter. Crumly & Associates Inc. now owns 1,146 shares of the medical research company’s stock valued at $320,000 after acquiring an additional 36 shares during the period. Maryland Capital Advisors Inc. raised its stake in shares of Amgen by 5.2% during the second quarter. Maryland Capital Advisors Inc. now owns 732 shares of the medical research company’s stock valued at $204,000 after acquiring an additional 36 shares during the last quarter. Finally, Lion Street Advisors LLC lifted its holdings in shares of Amgen by 1.3% during the second quarter. Lion Street Advisors LLC now owns 2,773 shares of the medical research company’s stock worth $774,000 after purchasing an additional 36 shares during the period. 76.50% of the stock is currently owned by institutional investors.

Amgen Trading Down 1.0%

NASDAQ AMGN opened at $334.30 on Tuesday. The stock has a market capitalization of $180.01 billion, a P/E ratio of 27.33, a P/E/G ratio of 2.61 and a beta of 0.45. The business has a 50 day simple moving average of $302.19 and a 200 day simple moving average of $293.02. The company has a debt-to-equity ratio of 7.24, a current ratio of 1.31 and a quick ratio of 0.98. Amgen Inc. has a one year low of $253.30 and a one year high of $345.84.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, November 4th. The medical research company reported $5.64 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.01 by $0.63. The firm had revenue of $9.56 billion for the quarter, compared to analyst estimates of $8.98 billion. Amgen had a return on equity of 174.71% and a net margin of 18.96%.The company’s revenue was up 12.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $5.58 earnings per share. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. Research analysts expect that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, December 12th. Investors of record on Friday, November 21st will be paid a dividend of $2.38 per share. The ex-dividend date of this dividend is Friday, November 21st. This represents a $9.52 annualized dividend and a yield of 2.8%. Amgen’s dividend payout ratio is currently 73.57%.

Insiders Place Their Bets

In other news, SVP Rachna Khosla sold 890 shares of the firm’s stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $336.24, for a total value of $299,253.60. Following the completion of the sale, the senior vice president directly owned 7,082 shares in the company, valued at $2,381,251.68. This trade represents a 11.16% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, EVP Murdo Gordon sold 6,879 shares of the business’s stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $336.83, for a total value of $2,317,053.57. Following the completion of the sale, the executive vice president directly owned 41,923 shares of the company’s stock, valued at $14,120,924.09. The trade was a 14.10% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 10,908 shares of company stock worth $3,674,966. 0.76% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on AMGN shares. UBS Group decreased their price objective on Amgen from $326.00 to $317.00 and set a “neutral” rating for the company in a report on Wednesday, August 6th. Weiss Ratings raised Amgen from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, October 8th. Citigroup raised their price objective on Amgen from $310.00 to $315.00 and gave the stock a “neutral” rating in a research report on Wednesday, September 24th. HSBC upped their target price on Amgen from $343.00 to $381.00 and gave the company a “buy” rating in a report on Wednesday, November 19th. Finally, Piper Sandler raised their price target on shares of Amgen from $342.00 to $381.00 and gave the stock an “overweight” rating in a report on Friday, November 14th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $320.86.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.